SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Vicuron Pharmaceuticals Inc – ‘10-K’ for 12/31/04 – EX-31.1

On:  Wednesday, 3/16/05, at 11:59am ET   ·   For:  12/31/04   ·   Accession #:  1193125-5-52270   ·   File #:  0-31145

Previous ‘10-K’:  ‘10-K’ on 3/15/04 for 12/31/03   ·   Latest ‘10-K’:  This Filing

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 3/16/05  Vicuron Pharmaceuticals Inc       10-K       12/31/04   11:1.1M                                   RR Donnelley/FA

Annual Report   —   Form 10-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML    966K 
 2: EX-10.23    Indemnity Agreement                                 HTML     49K 
 3: EX-10.32    Employment Agreement Between Versicor Inc. and      HTML     62K 
                          David S. Krause M.D.                                   
 4: EX-10.35    First Amendment to Employment Agreement for David   HTML     16K 
                          S. Krause                                              
 5: EX-12.1     Staement Re: Computation of Ratios                  HTML     10K 
 6: EX-21.1     List of Subsidiaries                                HTML     10K 
 7: EX-23.1     Consent of Pricewaterhousecoopers LLP               HTML      7K 
 8: EX-31.1     Secton 302 CEO Certification                        HTML     13K 
 9: EX-31.2     Section 302 CFO Certification                       HTML     12K 
10: EX-32.1     Section 906 CEO Certification                       HTML     10K 
11: EX-32.2     Section 906 CFO Certification                       HTML     10K 


EX-31.1   —   Secton 302 CEO Certification


This exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  Secton 302 CEO Certification  

Exhibit 31.1

 

CERTIFICATION PURSUANT TO RULES 13a-14(a) CERTIFICATION IN ACCORDANCE WITH

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, George F. Horner III, President and Chief Executive Officer of Vicuron Pharmaceuticals Inc. (the “Company”), certify that:

 

1. I have reviewed this annual report on Form 10-K of the Company;

 

2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;

 

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation; and

 

d) disclosed in this annual report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s fourth fiscal quarter of 2004 that has materially affected, or is reasonable likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

 

a) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: March 14, 2005

      /s/ GEORGE F. HORNER III
        George F. Horner III
        President and Chief Executive Officer

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:3/16/054
3/14/05
For Period End:12/31/04
 List all Filings 
Top
Filing Submission 0001193125-05-052270   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., Apr. 23, 6:40:47.1pm ET